These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

426 related articles for article (PubMed ID: 33681731)

  • 41. Outpatient treatment of COVID-19 with steroids in the phase of mild pneumonia without the need for admission as an opportunity to modify the course of the disease: A structured summary of a randomised controlled trial.
    Saiz-Rodríguez M; Peña T; Lázaro L; González Á; Martínez A; Cordero JA; Vicente JT; Richard F; Coma MJ; de Frutos M; Labrador J; Pueyo A
    Trials; 2020 Jul; 21(1):632. PubMed ID: 32646502
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Hydroxychloroquine for pre-exposure prophylaxis of COVID-19 in health care workers: a randomized, multicenter, placebo-controlled trial Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine (HERO-HCQ).
    Naggie S; Milstone A; Castro M; Collins SP; Lakshmi S; Anderson DJ; Cahuayme-Zuniga L; Turner KB; Cohen LW; Currier J; Fraulo E; Friedland A; Garg J; George A; Mulder H; Olson RE; O'Brien EC; Rothman RL; Shenkman E; Shostak J; Woods CW; Anstrom KJ; Hernandez AF;
    Int J Infect Dis; 2023 Apr; 129():40-48. PubMed ID: 36682681
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Safety and immunogenicity of a protein subunit COVID-19 vaccine (ZF2001) in healthy children and adolescents aged 3-17 years in China: a randomised, double-blind, placebo-controlled, phase 1 trial and an open-label, non-randomised, non-inferiority, phase 2 trial.
    Gao L; Li Y; He P; Chen Z; Yang H; Li F; Zhang S; Wang D; Wang G; Yang S; Gong L; Ding F; Ling M; Wang X; Ci L; Dai L; Gao GF; Huang T; Hu Z; Ying Z; Sun J; Zuo X
    Lancet Child Adolesc Health; 2023 Apr; 7(4):269-279. PubMed ID: 36803632
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Safety and efficacy of antiviral combination therapy in symptomatic patients of Covid-19 infection - a randomised controlled trial (SEV-COVID Trial): A structured summary of a study protocol for a randomized controlled trial.
    Panda PK; Bandyopadhyay A; Singh BC; Moirangthem B; Chikara G; Saha S; Bahurupi YA
    Trials; 2020 Oct; 21(1):866. PubMed ID: 33081849
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Testing the feasibility of operationalizing a prospective, randomized trial with remote cardiac safety EKG monitoring during a pandemic.
    Liu HH; Ezekowitz MD; Columbo M; Khan O; Martin J; Spahr J; Yaron D; Cushinotto L; Kapelusznik L
    J Interv Card Electrophysiol; 2022 Mar; 63(2):345-356. PubMed ID: 34037911
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Subcutaneous anti-COVID-19 hyperimmune immunoglobulin for prevention of disease in asymptomatic individuals with SARS-CoV-2 infection: a double-blind, placebo-controlled, randomised clinical trial.
    Alemany A; Millat-Martinez P; Corbacho-Monné M; Suñer C; Galvan-Casas C; Carrera C; Ouchi D; Prat N; Ara J; Nadal N; Riel R; Funollet B; Ojeda-Ciurana C; Balague LE; Salvador-González B; Arcarons AF; Vidal-Alaball J; Del Cura-González MI; Barrientos RR; Ramos-Blanes R; Bou AA; Mondou E; Torres M; Campins N; Sanz A; Tang Y; Rodriguez-Arias MÀ; Bassat Q; Clotet B; ; Mitjà O
    EClinicalMedicine; 2023 Mar; 57():101898. PubMed ID: 36936402
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Evaluation of the Effects of Remdesivir and Hydroxychloroquine on Viral Clearance in COVID-19 : A Randomized Trial.
    Barratt-Due A; Olsen IC; Nezvalova-Henriksen K; Kåsine T; Lund-Johansen F; Hoel H; Holten AR; Tveita A; Mathiessen A; Haugli M; Eiken R; Kildal AB; Berg Å; Johannessen A; Heggelund L; Dahl TB; Skåra KH; Mielnik P; Le LAK; Thoresen L; Ernst G; Hoff DAL; Skudal H; Kittang BR; Olsen RB; Tholin B; Ystrøm CM; Skei NV; Tran T; Dudman S; Andersen JT; Hannula R; Dalgard O; Finbråten AK; Tonby K; Blomberg B; Aballi S; Fladeby C; Steffensen A; Müller F; Dyrhol-Riise AM; Trøseid M; Aukrust P;
    Ann Intern Med; 2021 Sep; 174(9):1261-1269. PubMed ID: 34251903
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Test and treat COVID 65 plus - Hydroxychloroquine versus placebo in early ambulatory diagnosis and treatment of older patients with COVID19: A structured summary of a study protocol for a randomised controlled trial.
    Göpel S; Bethge W; Martus P; Kreth F; Iftner T; Joos S; Döbele S; Mordmüller B; Kremsner P; Ettrich T; Seufferlein T; Bitzer M; Malek N
    Trials; 2020 Jul; 21(1):635. PubMed ID: 32650818
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Natural tannin extracts supplementation for COVID-19 patients (TanCOVID): a structured summary of a study protocol for a randomized controlled trial.
    Molino S; Pisarevsky A; Mingorance FL; Vega P; Stefanolo JP; Repetti J; Ludueña G; Pepa P; Olmos JI; Fermepin MR; Uehara T; Villapol S; Savidge T; Treangen T; Viciani E; Castagnetti A; Piskorz MM
    Trials; 2021 Apr; 22(1):310. PubMed ID: 33910614
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Randomized double-blinded placebo-controlled trial of hydroxychloroquine with or without azithromycin for virologic cure of non-severe Covid-19.
    Omrani AS; Pathan SA; Thomas SA; Harris TRE; Coyle PV; Thomas CE; Qureshi I; Bhutta ZA; Mawlawi NA; Kahlout RA; Elmalik A; Azad AM; Daghfal J; Mustafa M; Jeremijenko A; Soub HA; Khattab MA; Maslamani MA; Thomas SH
    EClinicalMedicine; 2020 Dec; 29():100645. PubMed ID: 33251500
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Assessing the efficacy and safety of hydroxychloroquine as outpatient treatment of COVID-19: a randomized controlled trial.
    Schwartz I; Boesen ME; Cerchiaro G; Doram C; Edwards BD; Ganesh A; Greenfield J; Jamieson S; Karnik V; Kenney C; Lim R; Menon BK; Mponponsuo K; Rathwell S; Ryckborst KJ; Stewart B; Yaskina M; Metz L; Richer L; Hill MD;
    CMAJ Open; 2021; 9(2):E693-E702. PubMed ID: 34145052
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Treating COVID-19 With Hydroxychloroquine (TEACH): A Multicenter, Double-Blind Randomized Controlled Trial in Hospitalized Patients.
    Ulrich RJ; Troxel AB; Carmody E; Eapen J; Bäcker M; DeHovitz JA; Prasad PJ; Li Y; Delgado C; Jrada M; Robbins GA; Henderson B; Hrycko A; Delpachitra D; Raabe V; Austrian JS; Dubrovskaya Y; Mulligan MJ
    Open Forum Infect Dis; 2020 Oct; 7(10):ofaa446. PubMed ID: 33134417
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A Randomized Open label Phase-II Clinical Trial with or without Infusion of Plasma from Subjects after Convalescence of SARS-CoV-2 Infection in High-Risk Patients with Confirmed Severe SARS-CoV-2 Disease (RECOVER): A structured summary of a study protocol for a randomised controlled trial.
    Janssen M; Schäkel U; Djuka Fokou C; Krisam J; Stermann J; Kriegsmann K; Haberbosch I; Novotny JP; Weber S; Vehreschild M; Bornhäuser M; Bullinger L; Schmitt M; Liebregts T; Dreger P; Lorenz HM; Plaszczyca A; Bartenschlager R; Müller B; Kräusslich HG; Halama N; Jäger D; Schlenk RF; Leo A; Meuer S; Weigand MA; Motsch J; Merle U; Denkinger CM; Müller-Tidow C
    Trials; 2020 Oct; 21(1):828. PubMed ID: 33023671
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Favipiravir for Treatment of Outpatients With Asymptomatic or Uncomplicated Coronavirus Disease 2019: A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Trial.
    Holubar M; Subramanian A; Purington N; Hedlin H; Bunning B; Walter KS; Bonilla H; Boumis A; Chen M; Clinton K; Dewhurst L; Epstein C; Jagannathan P; Kaszynski RH; Panu L; Parsonnet J; Ponder EL; Quintero O; Sefton E; Singh U; Soberanis L; Truong H; Andrews JR; Desai M; Khosla C; Maldonado Y
    Clin Infect Dis; 2022 Nov; 75(11):1883-1892. PubMed ID: 35446944
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A Trial of Favipiravir and Hydroxychloroquine combination in Adults Hospitalized with moderate and severe Covid-19: A structured summary of a study protocol for a randomised controlled trial.
    Bosaeed M; Mahmoud E; Hussein M; Alharbi A; Alsaedy A; Alothman A; Aljeraisy M; Alqahtani H; Nashabat M; Almutairi B; Almaghaslah M; Aldibasi O; AlJohani S; Bouchama A; Arabi Y; Alaskar A
    Trials; 2020 Oct; 21(1):904. PubMed ID: 33129363
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Efficacy and safety of hydroxychloroquine in healthcare professionals with mild SARS-CoV-2 infection: Prospective, non-randomized trial.
    Agusti A; Guillen E; Ayora A; Anton A; Aguilera C; Vidal X; Andres C; Alonso M; Espuga M; Esperalba J; Gorgas MQ; Almirante B; Ribera E
    Enferm Infecc Microbiol Clin (Engl Ed); 2022; 40(6):289-295. PubMed ID: 35680347
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Azithromycin added to hydroxychloroquine for patients admitted to intensive care due to coronavirus disease 2019 (COVID-19)-protocol of randomised controlled trial AZIQUINE-ICU.
    Duška F; Waldauf P; Halačová M; Zvoníček V; Bala J; Balík M; Beneš J; Klementová O; Kozáková I; Kubricht V; Le Roy A; Vymazal T; Řehořová V; Černý V;
    Trials; 2020 Jul; 21(1):631. PubMed ID: 32641163
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19): a structured summary of a study protocol for a randomized controlled trial.
    Vallejos J; Zoni R; Bangher M; Villamandos S; Bobadilla A; Plano F; Campias C; Chaparro Campias E; Achinelli F; Guglielmone HA; Ojeda J; Medina F; Farizano Salazar D; Andino G; Ruiz Diaz NE; Kawerin P; Meza E; Dellamea S; Aquino A; Flores V; Martemucci CN; Vernengo MM; Martinez SM; Segovia JE; Aguirre MG
    Trials; 2020 Nov; 21(1):965. PubMed ID: 33234158
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Safety and tolerability of hydroxychloroquine in health care workers and first responders for the prevention of COVID-19: WHIP COVID-19 Study.
    McKinnon JE; Wang DD; Zervos M; Saval M; Marshall-Nightengale L; Kilgore P; Pabla P; Szandzik E; Maksimowicz-McKinnon K; O'Neill WW
    Int J Infect Dis; 2022 Mar; 116():167-173. PubMed ID: 34954095
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Outcomes after early treatment with hydroxychloroquine and azithromycin: An analysis of a database of 30,423 COVID-19 patients.
    Brouqui P; Million M; Parola P; Mccullough PA; Raoult D
    New Microbes New Infect; 2023 Oct; 55():101188. PubMed ID: 38024333
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.